An evaluation of selinexor’s clinical trial portfolio: a cross-sectional study

An evaluation of selinexor’s clinical trial portfolio: a cross-sectional study

Background: Cancer drug development is a complex and costly process. Selinexor is a drug that received accelerated approval as a new treatment for relapsed or refractory diffuse-large B-cell lymphoma and multiple myeloma. Despite initially showing promise in treating these conditions, it has shown h...

Full description

Saved in:

Bibliographic Details
Main Authors:	Annes Elfar, Andrew V. Tran, Joseph Case, Cole Wayant, Griffin K. Hughes, Ryan McIntire, Brooke Gardner, Chase Ladd, Andriana M. Peña, Jordan Tuia, Alyson Haslam, Vinay Prasad, Matt Vassar
Format:	Article
Language:	English
Published:	SAGE Publishing 2025-05-01
Series:	Therapeutic Advances in Hematology
Online Access:	https://doi.org/10.1177/20406207251329174
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Assessing patient risk, benefit, and outcomes in drug development: a decade of vemurafenib clinical trials
by: Taylor Gardner, et al.
Published: (2025-05-01)

Evidence of selective reporting bias in hematology journals: A systematic review.
by: Cole Wayant, et al.
Published: (2017-01-01)

Endorsement of reporting guidelines and clinical trial registration across urological medical journals: a cross-sectional study
by: Alex Hagood, et al.
Published: (2024-12-01)

Selinexor’s Immunomodulatory Impact in Advancing Multiple Myeloma Treatment
by: Kereshmeh Tasbihi, et al.
Published: (2025-03-01)

Selinexor in acute myeloid leukemia: therapeutic applications and current challenges
by: Ziyu Qie, et al.
Published: (2025-05-01)

Using the CONSORT statement to evaluate the completeness of reporting of addiction randomised trials: a cross-sectional review
by: Michael Bibens, et al.
Published: (2019-09-01)

Selinexor in Uveal Melanoma: A Hopeful Step or Just Another Hurdle?
by: Carlos Ayala de Miguel, et al.
Published: (2025-04-01)

Data sharing practices in high-impact rehabilitation journals
by: Ahmed Elghzali, et al.
Published: (2025-05-01)

Therapeutic Potential of Venetoclax and Selinexor in Targeting Hypoxia‐Induced Vulnerabilities in Multiple Myeloma
by: Seiichi Okabe, et al.
Published: (2025-06-01)

Network Meta-Analysis of Once Weekly Selinexor-Bortezomib-Dexamethasone in Previously Treated Multiple Myeloma
by: Michael Dolph, et al.
Published: (2021-08-01)

Innovative evaluation of selinexor and JQ1 synergy in leukemia therapy via C-MYC inhibition
by: Pei-Hong Wang, et al.
Published: (2025-05-01)

Selinexor combined with bortezomib, lenalidomide, and dexamethasone for the treatment of newly diagnosed multiple myeloma with extramedullary disease
by: Junjing Yin, et al.
Published: (2024-11-01)

A phase IIb study of selinexor in combination with daratumumab in patients with daratumumab-refractory multiple myeloma
by: Noa Biran, et al.
Published: (2025-04-01)

FRESCO–2 trial and fruquintinib: A clearer picture of the control arm
by: Sruthi Ranganathan, et al.
Published: (2025-08-01)

Targeting deubiquitinase USP7-mediated stabilization of XPO1 contributes to the anti-myeloma effects of selinexor
by: Junying Wang, et al.
Published: (2025-01-01)

Assessing the prevalence, quality and compliance of data-sharing statements in gastroenterology publications: a cross-sectional analysis
by: Matthew Vassar, et al.
Published: (2025-03-01)

A Phase IB Trial of Selinexor in Combination With Immune Checkpoint Blockade in Patients With Advanced Renal Cell Carcinoma
by: Omar Alhalabi, et al.
Published: (2025-02-01)

Enhanced skill learning via cervical transcutaneous vagus nerve stimulation: a neuroimaging perspective
by: Justin Kilmarx, et al.
Published: (2025-07-01)

Pre-Launch Thermal Emissive Band Radiometric Performance for JPSS-3 and -4 VIIRS
by: David Moyer, et al.
Published: (2024-12-01)

Bedside implications of the use of surrogate endpoints in solid and haematological cancers: implications for our reliance on PFS, DFS, ORR, MRD and more
by: Vinay Prasad, et al.
Published: (2024-09-01)

Analysis of the Political Viewpoint of Policy Statements From Professional Medical Organizations Using ChatGPT With GPT-4: Cross-Sectional Study
by: Ben Knudsen, et al.
Published: (2025-06-01)

Inclusion of key populations in clinical trials of new antituberculosis treatments: Current barriers and recommendations for pregnant and lactating women, children, and HIV-infected persons.
by: Amita Gupta, et al.
Published: (2019-08-01)

Selinexor in combination with venetoclax and decitabine in patients with refractory myelodysplastic syndrome previously exposed to hypomethylating agents: three case reports
by: Yunshuo Xiao, et al.
Published: (2024-12-01)

Family medicine journals’ endorsement of reporting guidelines and clinical trial registration: a cross-sectional analysis
by: Wyatt Compton, et al.
Published: (2024-12-01)

Land cover, more than monthly fire weather, drives fire-size distribution in Southern Québec forests: Implications for fire risk management.
by: Jean Marchal, et al.
Published: (2017-01-01)

Quantification of Total and Unbound Selinexor Concentrations in Human Plasma by a Fully Validated Liquid Chromatography-Tandem Mass Spectrometry Method
by: Suhyun Lee, et al.
Published: (2025-07-01)

The synergy of TPL and selinexor in MLL-R acute myeloid leukemia via Rap1/Raf/MEK pathway-mediated MYC downregulation
by: Manman Deng, et al.
Published: (2025-07-01)

NEXUS: a phase I dose escalation study of selinexor plus nivolumab and ipilimumab in Asian patients with advanced/metastatic solid malignancies
by: Joan R. Choo, et al.
Published: (2025-06-01)

A cross-sectional study on the endorsement of reporting guidelines and clinical trial registration among immunology and allergy journals.
by: Adam Khan, et al.
Published: (2025-01-01)

Real-World Treatment Patterns and Survival Outcomes of Patients with Relapsed/Refractory Multiple Myeloma Treated with a Selinexor-Containing Triplet-Based Regimen
by: Andrew Whiteley, et al.
Published: (2025-05-01)

Simple and accessible methods for quantifying isolated mucins for further evaluation
by: Hannah J. McIntire-Ray, et al.
Published: (2025-06-01)

Efficacy and safety of selinexor-based regimens as first-line treatments for elderly patients with diffuse large B-cell lymphoma: a real-world study
by: Jing Li, et al.
Published: (2025-05-01)

Modeling forest canopy structure and developing a stand health index using satellite remote sensing
by: Pulakesh Das, et al.
Published: (2024-12-01)

Retraction notice to “Identification of metabolites of brexpiprazole in human urine for use in monitoring patient compliance” [Clin. Mass Spectrom. 6 (2017) 21–24]
by: Jeffrey R. Enders, et al.
Published: (2025-04-01)

Corrigendum: Brain and serum lipidomic profiles implicate Lands cycle acyl chain remodeling association with APOEε4 and mild cognitive impairment
by: Jason Mares, et al.
Published: (2024-09-01)

Infinite Portfolio Strategies
by: Stephen F. LeRoy
Published: (2012-12-01)

Map Portfolio Project
by: Jackson Kelly
Published: (2025-01-01)

Introduction du portfolio
by: Direction CRH
Published: (2023-07-01)

Enhancing Portfolio Optimization: A Two-Stage Approach with Deep Learning and Portfolio Optimization
by: Shiguo Huang, et al.
Published: (2024-10-01)

Haploidentical Hematopoietic Stem Cell Transplantation for Relapsed/Refractory Extramedullary Multiple Myeloma: A Conditioning Regimen Combining Selinexor and Helical Tomotherapy—A Case Report and Literature Review
by: Chen B, et al.
Published: (2025-04-01)